Abstract: This invention concerns the use, for synthesizing and immobilising nucleic acids, of a solid support modified by an organized self-assembled monolayer of one or several organosilicon compounds. The invention also concerns methods for synthesizing and immobilizing nucleic acids on such a silanized solid support, and DNA chips obtained by said methods.
Type:
Grant
Filed:
January 17, 2001
Date of Patent:
December 27, 2005
Assignee:
Centre National da la Recherche Scientifique
Abstract: Compounds and pharmaceutical compositions active against HIV are provided, as is a method for the treatment of HIV infection in humans and other host animals is provided comprising administering an effective amount of a &bgr;-L-(2′ or 3′-azido)-2′,3′-dideoxy-5-fluorocytosine of the formula 1
Type:
Application
Filed:
June 18, 2002
Publication date:
February 20, 2003
Applicant:
The Centre National da la Recherche Scientifique
Inventors:
Gilles Gosselin, Jean-Louis Imbach, Jean-Pierre Sommadossi, Raymond F. Schinazi
Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula:
wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.
Type:
Grant
Filed:
December 10, 1999
Date of Patent:
September 3, 2002
Assignees:
Novirio Pharmaceuticals Limited, Centre National da la Recherche Scientifique
Inventors:
Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula:
wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.
Type:
Grant
Filed:
August 10, 1999
Date of Patent:
May 28, 2002
Assignees:
Novirio Pharmaceuticals Limited, Centre National da la Recherche Scientifique
Inventors:
Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant